Negative Pressure Wound Therapy

Coverage Summary

This policy defines UnitedHealthcare Commercial and Individual Exchange coverage positions for outpatient negative pressure wound therapy (NPWT) and applies to NPWT provided in the outpatient setting or upon discharge from inpatient care. NPWT (vacuum-assisted closure) uses a sealed dressing, suction pump, tubing, and a collection chamber to apply sub-atmospheric pressure to a wound to remove exudate, reduce bacterial contamination and edema, increase local blood flow, approximate wound edges, and promote granulation tissue. It is intended as an adjunct when wounds do not respond to conventional treatment. The policy is effective January 1, 2026 and is identified as policy number 2026T0594N.

Medical Necessity Criteria

General prerequisite — Complete wound therapy program

A complete wound therapy program, meeting the following criteria, must have been tried, or considered and ruled out prior to initiation of NPWT:

ALL of the following

Documentation of evaluation, care, and wound measurements.
Application of dressings to maintain a moist wound environment.
Debridement of necrotic tissue, if present.
Evaluation of and provision for adequate nutritional status.
Documentation, by provider, of indication for NPWT.
Documentation that open wound has not responded to conventional treatment after 30 days.

Indications — Pressure ulcer (Stage III or IV)

Covered when ALL of the following are met:

ALL of the following

Pressure ulcer Stage III or Stage IV as defined by NPIAP staging system.
Complete wound therapy program, as outlined above.
Appropriate turning and positioning.
Use of a pressure-reducing support surface.
Moisture and incontinence management.

Indications — Neuropathic ulcer (e.g., diabetic ulcer)

Covered when ALL of the following are met:

ALL of the following

Neuropathic ulcer (e.g., diabetic foot ulcer).
Complete wound therapy program, as outlined above.
Comprehensive diabetic management program.
Reduction in pressure on the ulcer (offloading).

Indications — Venous insufficiency ulcer

Covered when ALL of the following are met:

ALL of the following

Venous insufficiency ulcer.
Complete wound therapy program, as outlined above.
Compression bandages and/or garments have been used consistently for at least 30 days.
Leg elevation and ambulation.

Indications — Open surgical wound

Covered when ANY of the following postoperative or graft-related conditions are documented:

ANY of the following

Post-operative dehiscence (separation of a previously closed surgical incision) with documentation of a complete wound therapy program, as outlined above.
Open, non-healing amputation site in diabetics.
Post-sternotomy infection (mediastinitis).
Delayed healing or non-healing of a skin graft likely due to irregularly contoured or inadequate blood flow of the graft bed.

Indications — High-risk open fracture

Covered when ALL of the following are met:

ALL of the following

High-risk open fracture (Gustilo Grade III).
Documentation of a complete wound therapy program, as outlined above.

Not medically necessary / Unproven indications

The following indications and devices are considered unproven and not medically necessary due to insufficient evidence of efficacy:

ANY of the following

NPWT for treating all other indications not listed as proven, including but not limited to closed surgical incisions and pilonidal disease.
Disposable/single-use NPWT systems.
NPWT systems with instillation of wound solutions.

Contraindications (absolute or require discontinuation)

NPWT is contraindicated in the presence of any of the following:

ANY of the following

Active bleeding or exposed vasculature in the wound.
Anticoagulation therapy (relative contraindication requiring careful consideration).
May require discontinuation or specialist input based on bleeding risk.
Eschar or necrotic tissue present in the wound.
Exposed bone, nerves, or organs within the vicinity of the wound.
Malignancy present in the wound.

Discontinuation criteria

NPWT should be discontinued when ANY of the following criteria are present:

ANY of the following

Documentation of weekly assessment of the wound's dimensions and characteristics by the provider indicates failure of progressive wound healing (i.e., wound is not diminishing in size — surface area or depth — within 30 days).
Uniform granulation tissue has been obtained.
Depth of the wound is 1 mm or less.Depth <= 1 mm

Coverage Considerations (contextual evidence summary)

Contextual evidence summary and coverage considerations:

ALL of the following

NPWT is intended as an adjunct for wounds that have not responded to conventional treatment (e.g., debridement, pressure relief, infection control).
Evidence is limited for some indications; consensus recommendations exist to guide initiation and device selection.
Disposable/single-use NPWT systems and NPWT with instillation have emerging but insufficient evidence; these are considered unproven/not medically necessary pending stronger data.
Provider documentation must support that a complete wound therapy program was attempted or considered and ruled out, and include wound measurements, debridement status, nutritional assessment, and rationale for NPWT.

Coverage Considerations & Evidence Summary

Evidence and guideline recommendations for NPWT vary by indication and are generally conditional. Systematic reviews, meta-analyses, and guideline panels report mixed quality evidence across wound types — some studies and meta-analyses suggest benefit for diabetic foot wounds, pressure injuries Stage III/IV, and selected surgical or open-wound applications, whereas other trials (for example, lower limb incisional NPWT trials) show no clear benefit. Guideline statements (IWGDF, SVS, NPIAP, NICE, WHS) recommend considering NPWT in specific situations (often weak or conditional recommendations) such as post-operative diabetic foot wounds that fail standard therapy, stage III/IV pressure injuries that do not progress, or selective high-risk closed incisions. Coverage decisions under this policy are therefore indication-specific and depend on whether required prior wound care and documentation are met, and they must be reconciled with the member specific benefit plan and any applicable mandates.

Evidence	Key takeaways
Kirsner et al. (2019)
Single-use NPWT showed superiority to traditional NPWT for wound progression in a 164-patient RCT; compared NPWT types rather than NPWT vs standard care; limited by small size and short follow-up.
Cochrane (pressure ulcers)
Very low-certainty evidence; efficacy and safety of NPWT for pressure ulcers uncertain due to limited data and small trials.
Meta-analyses (diabetic foot ulcers)
Systematic reviews/meta-analyses report NPWT may improve healing and reduce amputations vs moist wound care, but overall evidence quality is variable and trials are often small or heterogeneous.
WHIST RCT (Costa 2020)
Multicenter RCT of incisional NPWT vs standard dressing in lower limb fractures found no significant benefit for deep SSI or long-term patient-reported outcomes.
Ensor RCT (2024) - pilonidal disease
RCT found no difference in surgical wound dehiscence or time to healing for pilonidal disease; NPWT not recommended to prevent SWD; small sample size.
De Pellegrin 2023 (NPWTi-d meta-analysis)
NPWT with instillation (NPWTi-d) showed higher primary wound closure and fewer complications versus NPWT/standard care in meta-analysis, but studies were heterogeneous and limited quality; larger RCTs needed.
Gabriel et al. (2021) / Kanapathy et al. (2020)
Systematic reviews of NPWTi-d report improved debridement requirements, bioburden reduction, and closure rates across varied wound types but evidence is low quality and heterogeneous.

Coding

NPWT service CPT codes (for reference)CPTCovered

97605	Negative pressure wound therapy, utilizing durable medical equipment (DME), per session; total wound(s) surface area <= 50 sq cm
97606	Negative pressure wound therapy, utilizing DME, per session; total wound(s) surface area > 50 sq cm
97607	Negative pressure wound therapy, utilizing disposable, non-durable medical equipment, per session; total wound(s) surface area <= 50 sq cm
97608	Negative pressure wound therapy, utilizing disposable, non-durable medical equipment, per session; total wound(s) surface area > 50 sq cm

NPWT supply and pump HCPCS / A-codes / E-codeHCPCSCovered

A6550	Wound care set, for negative pressure wound therapy electrical pump, includes all supplies and accessories
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each
E2402	Negative pressure wound therapy electrical pump, stationary or portable

Suction pump and dressing codes clarificationHCPCS

K0743-K0746

Suction pumps and dressing codes apply to devices other than NPWT (coding clarification noted)

Informational - FDA product code referencemixed

OMP	FDA product code for NPWT systems (informational link provided)

Provider Actions & Billing Impact

Prior Authorization

Prior authorization implication (outpatient coverage applies)

Outpatient NPWT (including use upon discharge from inpatient care) may require prior authorization. Medical records documentation may be requested to confirm the member meets the clinical criteria for outpatient coverage.

Applies to outpatient setting and upon discharge from inpatient care
Medical records documentation may be requested for review to assess clinical criteria

Documentation Required

Document prior complete wound therapy program

Document a prior complete wound therapy program before initiating NPWT. Records should show the components below have been tried, considered, or ruled out.

Definitions

Negative pressure wound therapy (NPWT) applies continuous or intermittent sub-atmospheric pressure to a wound via dressings, a pump, tubing, and a collection chamber to assist healing by removing exudate, reducing bacterial contamination and edema, increasing local blood flow, approximating wound edges, and promoting granulation tissue.

Gustilo Grade III Fracture: An open fracture with extensive soft-tissue damage or an open segmental fracture; IIIA: adequate soft tissue coverage despite extensive laceration; IIIB: extensive soft-tissue loss with periosteal stripping and bone exposure often requiring flap; IIIC: arterial injury requiring repair.

NPIAP Stage III: Full-thickness loss of skin with visible fat in the ulcer; fascia, muscle, tendon, ligament, cartilage, and/or bone are not exposed; undermining and tunneling may occur.

NPIAP Stage IV: Full-thickness skin and tissue loss with exposed or directly palpable fascia, muscle, tendon, ligament, cartilage, or bone in the ulcer.

NPWTi-d: Negative pressure wound therapy with instillation and dwell time (NPWT with instillation of wound solutions).

Single-use NPWT: Disposable, closed-incision negative pressure wound therapy systems (e.g., PICO, Prevena).

Revision History

01/01/2026template updateLatest

Template Update: Created shared policy version to support application to Oxford plan membership and archived previous policy versions 2025T0594M and SURGERY 110.13. Administrative/template update; archived prior versions.